novel strategy described identify isolate cdna encode target antigens cytotoxic lymphocytes specific human prostate tumors emphasis placed antigens shared different prostate tumors molecules may basis broadly effective vaccines prevention therapy prostate cancer initial focus vitro models multiple prostate epithelial tumors derived treatment anchorage dependent contact inhibited nontumorigenic prostate epithelial cell line different carcinogens oncogene transformation comparison primary tumors vitro selected tumor lines advantage subject immunoselection vivo may preserve expression potentially important tumorspecific antigens addition availability panel control cell lines greatly facilitates design wellcontrolled identify carcinogen independent tumor antigens proposed commercial applications research directed developing vaccines prevention therapy prostate cancer